by Institute for Personalized Medicine | Aug 22, 2017 | Bredesen Papers
Abstract Key Alzheimer’s disease-related protein may be a transcriptional regulator. The allele apolipoprotein E c4 (APOE £4) is the greatest genetic risk factor for Alzheimer’s disease (AD), but the role of the ApoE4 protein in AD has long been elusive. Turns out,...
by Institute for Personalized Medicine | Aug 22, 2017 | Bredesen Papers
Abstract A major unanswered question in biology and medicine is the mechanism by which the product of the apolipoprotein E ! 4 allele, the lipid-binding protein apolipoprotein E4 (ApoE4), plays a pivotal role in processes as disparate as Alzheimer’s disease (AD; in...
by Institute for Personalized Medicine | Aug 22, 2017 | Bredesen Papers
Abstract Stan had discovered and coined the term prions in 1982, and when I established my own laboratory in 1989, I wanted to address two related questions: First, why do neurons degenerate in neurodegenerative diseases such as Creutzfeldt-Jakob disease...
by Institute for Personalized Medicine | Aug 22, 2017 | Bredesen Papers
Abstract To date, no truly effective therapy has been developed for Alzheimer’s disease or mild cognitive impairment. In searching for new approaches that may succeed where previous ones have failed, it may be instructive to consider the successful therapeutic...
by Institute for Personalized Medicine | Aug 22, 2017 | Bredesen Papers
Abstract Alzheimer’s disease is one of the most significant healthcare problems nationally and globally. Recently, the first description of the reversal of cognitive decline in patients with early Alzheimer’s disease or its precursors, MCI (mild cognitive impairment)...
